Safety and Efficacy of Efavaleukin Alfa in Subjects With Active Rheumatoid Arthritis

Summary

Phase 1b. To evaluate the safety and tolerability of subcutaneous (SC) dose administrations of Efavaleukin alfa in subjects with active rheumatoid arthritis (RA). Phase 2a. To evaluate the efficacy of Efavaleukin alfa at week 12 as measured by the American College of Rheumatology 20 percent improvement criteria (ACR 20) in adult subjects with moderate to severe RA.

Timeline

Start

2018-05-22

Primary completion

2019-12-10

Completion

2020-05-13

Outcome

Outcome not reported

Stopped (Business): “Amgen made a business decision not to proceed with Phase 2.”

Drugs

Indications